Spots Global Cancer Trial Database for Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer

Official Title: An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer

Study ID: NCT02009605

Conditions

Squamous Cell Carcinoma of Lung

Interventions

Icotinib

Study Description

Brief Summary: This study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer.

Detailed Description: This study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, confirmed at least 28 days following the date of the initial response.